Drugs / Sensoril
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01311180 | Mar 2011 → Nov 2012 | generalized anxiety disorder | Natreon, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00761761 | Oct 2008 → Mar 2011 | bipolar I disorder, bipolar II disorder | University of Pittsburgh | Completed | Mixed |
| Phase not applicable1 trial | ||||||
| — | NCT01793935 | Apr 2013 → Jul 2016 | schizoaffective disorder, schizophrenia | K.N. Roy Chengappa | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sensoril | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01793935 ↗ |
| Route | Oral | “oral Sensoril®” NCT00761761 ↗ |